Influence of visual field testing frequency on detection of glaucoma progression with trend analyses

Archives of Ophthalmology

Volumn 129, Issue 12, 2011, Pages 1521-1527

  Nouri Mahdavi, Kouros ^a   Zarei, Reza ^a   Caprioli, Joseph ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; DISEASE COURSE; EYE EXAMINATION; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VISUAL FIELD;

AGED; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; PROPORTIONAL HAZARDS MODELS; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 83455212197     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.224     Document Type: Article

References (16)

1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487-497.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
3. Lichter PR, Musch DC, Gillespie BW, et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
4. Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2009;50(4):1497-1505.
5. Boden C, Blumenthal EZ, Pascual J, et al. Patterns of glaucomatous visual field progression identified by three progression criteria. Am J Ophthalmol. 2004;138(6):1029-1036. (Pubitemid 40040020)
6. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118(9):1187-1194.
7. Heijl A, Bengtsson B, Hyman L, Leske MC; Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009;116(12):2271-2276.
8. Chauhan BC, Garway-Heath DF, Goñi FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92(4):569-573. (Pubitemid 351497993)
9. Gardiner SK, Crabb DP. Frequency of testing for detecting visual field progression. Br J Ophthalmol. 2002;86(5):560-564. (Pubitemid 34454504)
10. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 1: study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15(4):299-325.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310. (Pubitemid 16134762)
12. Gardiner SK, Crabb DP. Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci. 2002;43(5):1400-1407. (Pubitemid 34462637)
13. Nouri-Mahdavi K, Caprioli J, Coleman AL, Hoffman D, Gaasterland D. Pointwise linear regression for evaluation of visual field outcomes and comparison with the advanced glaucoma intervention study methods. Arch Ophthalmol. 2005;123(2):193-199. (Pubitemid 40189706)
14. Heijl A, Lindgren A, Lindgren G. Test-retest variability in glaucomatous visual fields. Am J Ophthalmol. 1989;108(2):130-135. (Pubitemid 19197944)
15. Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Visual field progression in glaucoma: total versus pattern deviation analyses. Invest Ophthalmol Vis Sci. 2005;46(12):4600-4606. (Pubitemid 44264560)
16. Manassakorn A, Nouri-Mahdavi K, Koucheki B, Law SK, Caprioli J. Pointwise linear regression analysis for detection of visual field progression with absolute versus corrected threshold sensitivities. Invest Ophthalmol Vis Sci. 2006;47(7):2896-2903. (Pubitemid 351639764)